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Abstract
A total of 1623 clinical isolates of Salmonella belonging to 229 serotypes were received by the Senegalese Reference Center for Enterobacteria
from January 1999 to December 2009. The most common serotypes were Enteritidis (19% of the isolates), Typhi (8%), Typhimurium (7%) and
Kentucky (4%). A signiﬁcant increase in the prevalence of resistance to amoxicillin (0.9% in 1999 to 11.1% in 2009) and nalidixic acid (0.9% in
1999 to 26.7% in 2009) was observed in non-typhoidal Salmonella serotypes. For critically important antibiotics, notably ciproﬂoxacin and
extended-spectrum cephalosporins (ESCs), the rates of resistance were low: 0.3% and 0.5%, respectively. Seven ESC-resistant Salmonella
strains and three additional ESC-resistant strains from Senegal (1990) and Mali (2007) were studied to identify the genetic basis of their
antibiotic resistance. All ESC-resistant strains produced an extended-spectrum b-lactamase (ESBL). These were CTX-M-15 (n = 6; 2000–
2008), SHV-12 (n = 3; 2000–2001) and SHV-2 (n = 1; 1990). A large IncHI2 ST1 pK29-like plasmid was found in six strains (three producing
SHV-12 and three CTX-M-15), whereas IncN and IncF plasmids were found in three strains and one strain, respectively. The association of
plasmid-mediated quinolone resistance (PMQR) genes qnrB1 and aac(6′)-Ib-cr was found in four ESBL-producing strains, leading to decreased
susceptibility and even full resistance to ciproﬂoxacin (MIC range 0.75–2 mg/L) despite the absence of mutations in the quinolone
resistance-determining region (QRDR) of gyrA, gyrB, parC and parE. This association of ESBL and multiple PMQR mechanisms within the same
strains is therefore a serious concern as it hampers the use of both ESCs and ﬂuoroquinolones for severe Salmonella infections.
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Introduction
Human Salmonella infections are generally either typhoid
fever, a systemic disease caused by S. enterica serotypes
Typhi, Paratyphi A, Paratyphi B (non-d-tartrate-fermenting
variant) and Paratyphi C, or gastroenteritis caused by a large
number of non-typhoidal Salmonella (NTS) serotypes. Typhoi-
dal serotypes are human-restricted whereas NTS have large
animal reservoirs. Although most salmonellosis due to NTS is
self-limiting, serious complications, including systemic infec-
tion and death, can occur. Such infections have consistently
been reported as a leading cause of bacteraemia in Africa and
are associated with a high risk of death [1]. As rates of
resistance to all classes of antibiotics have increased
throughout the world, conventional antibiotics such as
ampicillin, chloramphenicol and cotrimoxazole are no longer
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the appropriate choices and extended-spectrum cephalospo-
rins (ESCs) and ﬂuoroquinolones have become standard for
ﬁrst-line empirical treatment in children and adults, respec-
tively [2]. Recently, ESC-resistant (ESCR) Salmonella popula-
tions have emerged and spread over all continents, including
Africa [2–15]. This resistance is mainly mediated by acquired
extended-spectrum b-lactamase (ESBL) genes carried by
mobile genetic elements such as plasmids and transposons.
This situation is of great concern, as ESBL enzymes can
hydrolyze almost all b-lactams (except carbapenems and
cephamycins), and are frequently associated with genes
conferring resistance to several other classes of antibiotics.
Recently, plasmid-mediated quinolone resistance (PMQR) has
emerged in Enterobacteriaceae. Four PMQR mechanisms
have been described: Qnr, AAC(6′)-Ib-cr (AACA4-cr),
OqxAB and QepA, which mediate target protection (Qnr),
drug modiﬁcation (AAC(6′)-Ib-cr) and drug efﬂux (OqxAB
and QepA) [16]. These mechanisms result in an increase of
the minimum inhibitory concentration (MIC) of ﬂuoroquinol-
ones, thereby facilitating the selection of mutants with higher
levels of resistance in the presence of quinolones through
sequential chromosomal mutations in genes coding for the
target enzymes, DNA gyrase and/or DNA topoisomerase IV
[16].
Few data are available regarding the prevalence of ESCR
Salmonella strains in Africa or their antibiotic resistance gene
content and their genetic support. Such information is
important for an understanding of the spread of multi-
drug-resistant Salmonella spp.. Here, we report the prevalence
of resistance to antibiotics in Salmonella spp. isolated from
Senegalese patients between 1999 and 2009, and the genetic
basis for this antibiotic resistance. Three additional ESCR
strains from Senegal (1990) and from Mali (2007) were also
included to provide a better description of circulating
ESBL-producing Salmonella strains in West Africa.
Materials and Methods
Bacterial strains, serotyping and susceptibility
A total of 1623 S. enterica clinical isolates were received
between January 1999 and December 2009 by the Senegal-
ese Reference Center for Enterobacteria (Institut Pasteur,
Dakar, Senegal) from four major public and private clinical
laboratories (Ho^pital Aristide Le Dantec, Ho^pital Principal,
Institut Pasteur and Bio24) located in Dakar. If more than
one isolate with the same serotype and antimicrobial
resistance phenotype was recovered from the same patient,
only the ﬁrst was included. Epidemiological data (date and
site of isolation, age and gender of the patient) were
recorded for each ESCR isolate. ESCR Salmonella strains from
other collections were also included in this study: one strain
(09-7364) isolated in Senegal in 1990 (Poitiers University
Hospital collection, France) and two strains (07-0319,
07-1331) acquired in Mali in 2007 (the collection of the
French National Reference Center for Salmonella, Institut
Pasteur, Paris).
Strains were serotyped on the basis of somatic O and both
phase 1 and phase 2 ﬂagellar antigens by agglutination tests
with antisera (Bio-Rad, Marnes-La-Coquette, France) as
speciﬁed by the White-Kauffmann-Le Minor scheme [17].
Antibiotic susceptibility to amoxicillin, amoxicillin-clavulanic
acid, ticarcillin, cefalotin, cefoxitin, cefotaxime, ceftazidime,
amikacin, tobramycin, gentamicin, nalidixic acid, ciproﬂoxacin,
chloramphenicol, sulphonamides, cotrimoxazole and tetra-
cycline was determined by the disk diffusion method on
Mueller-Hinton agar (Bio-Rad) according to the guidelines of
the French Society for Microbiology. (http://www.sfm-micro
biologie.org/UserFiles/ﬁle/CASFM/casfm_2011.pdf).
All strains of Salmonella showing resistance to cefotaxime
and/or ceftazidime were selected for further analysis. Addi-
tional testing was carried out on these strains: (i) susceptibility
to piperacillin, piperacillin/tazobactam, imipenem and strepto-
mycin was determined by the disk diffusion method as
described above; (ii) they were tested for an ESBL enzyme
by the double disk synergy method [18]; and (iii) MICs for
nalidixic acid, ciproﬂoxacin, ceftriaxone and ceftazidime were
determined by using Etest strips (bioMerieux, Marcy L’Etoile,
France). The CA-SFM cut-off values were used for categori-
zation. Susceptible strains were deﬁned by MIC ≤ 8 mg/L for
nalidixic acid, MIC ≤ 0.5 mg/L for ciproﬂoxacin, MIC ≤ 1 mg/
L for ceftriaxone and MIC ≤ 4 mg/L for ceftazidime, and
resistant strains by MIC > 16 mg/L for nalidixic acid,
MIC > 1 mg/L for ciproﬂoxacin, MIC > 2 mg/L for ceftriax-
one and MIC > 4 mg/L for ceftazidime.
Characterization of resistance determinants in ESCR strains
Total DNA was extracted using the InstageneTM Matrix kit
(Bio-Rad) according to the manufacturer’s recommendations.
The resistance genes, blaTEM, blaSHV, blaCTX-M, blaOXA-1 group,
qnrA, qnrB, qnrS, qnrD, aac(6′)-Ib and qepA, were ampliﬁed by
PCR from DNA from all ESCR strains as described previously
[5,19]. For all qnr-positive ESCR strains, the quinolone
resistance-determining region (QRDR) of gyrA, gyrB, parC and
parE (encoding subunits of the DNA gyrase and topoisomerase
IV) was sequenced, as described previously [19]. The nucle-
otide and deduced amino acid sequences were analysed and
compared with sequences available through the Internet on
the National Center for Bio-technology Information web site
(http://www.ncbi.nlm.nih.gov).
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Molecular typing
Pulsed-ﬁeld gel electrophoresis (PFGE) of XbaI-digested chro-
mosomal DNA was performed for ESCR strains of serotypes
Kentucky and Agona, as previously described [6].
Resistance transfer determination of ESCR strains
Resistance transfer experiments were carried out on solid
media using either Escherichia coli K12 J5 resistant to sodium
azide or E. coli C1a resistant to nalidixic acid as the recipient
strain [5,10]. Transconjugants were selected on Drigalski agar
(Bio-Rad) supplemented with sodium azide (500 mg/L) and
ceftriaxone (2 mg/L) or ceftazidime (4 mg/L) or ciproﬂoxacin
(0.06 mg/L). Three E. coli transconjugants were arbitrarily
selected in each experiment.
Plasmid analysis
Plasmid DNA extracted by alkaline lysis was analysed by
electrophoresis in 0.8% agarose gels [5]. We used S1 nuclease
treatment and PFGE to determine the sizes of bacterial
plasmids, in parental and transconjugant strains, as described
previously [10]. PCR-based replicon-typing analysis was per-
formed as described previously [20]. Subtyping of plasmids was
carried out by plasmid MLST (pMLST) (http://pubmlst.org/
plasmid/) and multiplex PCR [21].
Statistical analysis
The chi-square test for trend was used to compare rates of
resistance to antibiotics during the study period. p values of
≤0.05 were considered statistically signiﬁcant. All analyses
were performed using STATA 12.0 (Stata Corporation,
College Station, TX, USA).
Results
Serotype distribution and antimicrobial susceptibility data
A total of 1623 independent isolates of Salmonella belonging to
229 serotypes were collected during the 11-year study period.
The most common serotypes were Enteritidis (19% of the
isolates), Typhi (8%), Typhimurium (7%) and Kentucky (4%)
(Table 1). Most of the isolates were from stools (n = 1281,
78.6%) and blood (n = 191, 11.7%). Among Salmonella blood
isolates, 118 (61.8%) were NTS, with Enteritidis (30.5% of the
isolates) and Typhimurium (15.8%) being the predominant
serotypes. The high prevalence of serotypes Kentucky in 2003
(12% of the total) and Poona (17%) in 2006 were due to
documented food poisoning episodes.
Overall, the 1476 NTS isolates had low or moderate
resistance to antibiotics. However, a signiﬁcant increase in the
prevalence of resistance to amoxicillin (0.9% in 1999 to 11.1% T
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in 2009) (p < 0.0001) and nalidixic acid (0.9% in 1999 to 26.7%
in 2009) (p < 0.0001) was observed during the study period
(Table 2). Four (0.3% of the total) NTS isolates belonging to
serotypes Keurmassar (2000, n = 1) (MIC of 1.5 mg/L) [4],
Enteritidis (2007, n = 1) (MIC of 1.25 mg/L) and Kentucky
(2009, n = 2) (MIC of 3 and >12 mg/L) were resistant to
ciproﬂoxacin; one of these isolates was ESCR (Keurmassar). All
the serotype Typhi (n = 127), Paratyphi A (n = 19) and
Paratyphi B (n = 1) isolates were susceptible to all antibiotics
tested, except for ﬁve serotype Paratyphi A isolates: three
were resistant to tetracycline, one was resistant to amoxicillin
and another one to cotrimoxazole. Eight NTS strains (0.5% of
the total) belonging to serotypes Keurmassar (n = 1, 2000)
[4], Kentucky (n = 2, 2000 and 2002) [5], Agona (n = 2, 2000
and 2001), Grumpensis (n = 1, 2008), Typhimurium (n = 1,
2008) and Carmel (n = 1, 2009) were resistant to all the
b-lactams tested, except for cefoxitin, piperacillin-tazobactam
and imipenem. Both serotype Kentucky strains were previ-
ously shown to display identical PFGE proﬁles and antimicro-
bial susceptibility proﬁles [5], whereas the two serotype
Agona strains had two similar but not identical PFGE proﬁles
(not shown) and different antimicrobial susceptibility proﬁles.
Therefore, only one serotype Kentucky strain but both
serotype Agona strains were selected for further molecular
investigation. These seven ESCR strains, as well as three
additional ESCR strains from Mali and Senegal (belonging to
serotypes Miami, Havana and Telelkebir), scored positive in
double-disk synergy tests and showed resistance to several
classes of antibiotics (Table 3). In particular, ﬁve strains were
resistant to nalidixic acid and three of these ﬁve were
resistant to ciproﬂoxacin (MIC 1.5–2 mg/L); three were
resistant to all but one of the aminoglycosides (amikacin)
tested.
Resistance determinants in ESCR strains
Among the 10 ESCR isolates, the blaCTX-M-15 gene was
detected in all of those isolated between 2007 and 2009
(n = 5), and also in one strain isolated in 2000, whereas
blaSHV-12 was detected in three strains isolated in 2000 and
2001, and blaSHV-2 in the oldest strain from 1990 (Table 3).
The qnr gene was present in ﬁve ESCR isolates (62%): two
were qnrB2 and three were qnrB1. The qnrB1 gene was
associated with the blaCTX-M-15 gene, and qnrB2 with the
blaSHV-12 gene. No qnr was found in the oldest strain that
produces SHV-2. The ﬁve qnr-positive strains had wild-type
alleles in the QRDR of gyrA, gyrB, parC and parE. They displayed
MICs to nalidixic acid in the range 24–64 mg/L, and MICs to
ciproﬂoxacin of 0.25–2 mg/L. According to CA-SFM break-
points, three were classiﬁed as resistant to ciproﬂoxacin (MICs
1.5–2 mg/L), one as susceptible (MIC of 0.25 mg/L) and one as
intermediate (MIC of 0.75 mg/L) (Table 3). The presence of
both qnr and aac(6′)-Ib-cr was associated with higher MICs to
ciproﬂoxacin (MICs 0.75–2 mg/L).
Genetic support of resistance determinants
The conjugation experiments showed that all the ESBL genes
and qnr genes were transferred into E. coli recipients (Table 3).
The blaCTX-M-15 genes were located on plasmids of the
incompatibility groups HI2 (n = 3; all assigned to ST1), n
(n = 2; both assigned to ST6) and F (n = 1; assigned to F2:A-:
B-). Both qnrB1 and the aac(6)′-Ib-cr genes were on large
IncHI2 plasmids (280–340 kb) also carrying the blaCTX-M-15
gene. The penicillinase blaOXA-1 and blaTEM genes were also
present on the large IncHI2 plasmid.
For the three SHV-12-producing S. enterica serotype Agona
and Keurmassar strains and their transconjugants, both one
IncHI2 ST1 plasmid and a second plasmid (IncI1 for serotype
TABLE 2. Percentage of resistance to speciﬁc antibiotics in non-typhoidal Salmonella serotypes in Dakar, Senegal, from 1999 to
2009
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Number of isolates tested 112 119 198 281 132 202 134 114 93 46 45 p value
Amoxicillin 0.9 2.5 1.0 1.1 0.8 7.9 2.2 1.8 4.3 8.7 11.1 <0.0001
Cefoxitin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 >0.5
Cefotaxime 0.0 2.5 0.5 0.4b 0.0 0.0 0.0 0.0 0.0 4.3 2.2 >0.5
Ceftazidime 0.0 2.5 0.5 0.4b 0.0 0.0 0.0 0.0 0.0 4.3 2.2 >0.5
Amikacin 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 >0.5
Tobramycin 0.0 7.6 1.0 1.4 0.0 0.5 0.0 0.0 0.0 4.3 8.7 >0.5
Gentamicin 0.0 7.6 1.0 1.4 0.0 0.5 0.0 0.0 0.0 8.7 4.3 >0.5
Nalidixic acid 0.9 0.0 2.5 1.4 0.8 4.0 8.2 4.4 4.3 15.2 26.7 <0.0001
Ciproﬂoxacin 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 4.4 >0.5
Chloramphenicol a 12.6 3.5 6.0 1.5 2.0 0.7 2.6 3.2 6.5 4.4 >0.5
Sulphonamide a a a a a 14.9 21.6 18.4 29.0 37.0 33.3 >0.5
Cotrimoxazole 5.4 21.0 9.6 10.0 6.1 7.4 9.7 7.0 6.5 17.4 8.9 >0.5
Tetracycline 67.0 26.1 15.7 8.9 5.3 5.9 14.2 6.1 10.8 10.9 28.9 >0.5
aNot tested.
bThis resistance corresponds to the CTX-M-15-producing S. enterica serotype Kentucky strain M08028, which was erroneously reported in reference 5 as having been isolated in
2001.
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Agona strains and IncF for serotype Keurmassar strain) were
detected. In the absence of southern blot and hybridization
with speciﬁc probes, we cannot determine the exact location
of the blaSHV-12 gene; however, it is probable that this gene is
carried by at least the IncHI2 plasmid, which was common to
the three SHV-12-producing strains.
The S. enterica serotype Miami strain had a blaSHV-2 gene on
an IncN (ST16) plasmid.
Discussion
In total, 1623 non-duplicate Salmonella spp. isolates were
analysed during the study period. Overall, the resistance rates
to all antibiotic classes were low or moderate although there
was a worrying increase in the prevalence of resistance to
certain ﬁrst-line antibiotics during the study period. The
prevalence of ESCR isolates in our study was 0.5%, consistent
with previous studies elsewhere in the world (0–2.4%) [2,22–
24]. National surveillance systems are primarily based on a
network of clinical laboratories that refer Salmonella isolates to
public health laboratories for identiﬁcation and susceptibility
testing. However, such systems are lacking in most countries
with inadequate healthcare systems. Consequently, many
studies in Africa are not appropriately representative of the
epidemiological situation nationally. Despite these limitations,
the number of new cases of ESCR Salmonella strains (novel
associations of serotype, enzyme and country) seems to have
increased across Africa since the ﬁrst description in 1988 in
Tunisia [3]. So far, 23 different Salmonella serotypes producing
ESBLs have been described in studies of human isolates in
West Africa [2,4–6], Maghreb [2,3,9,12,13,15], East Africa
[2,8,10,11], South Africa [7,14] and Central Africa (S. Breurec,
unpublished data). Typhimurium is the most frequently isolated
ESBL-producing serotype in these ten African countries.
ESBL-producing Salmonella can be acquired in the community
[2,5,7,12] or in hospitals [2,8,9,13], in particular in paediatric
wards and neonatology units.
Several reports also mention internationally adopted chil-
dren from Mali or Ethiopia as carriers of ESBL-producing
Salmonella of various serotypes [6,10,11]. Such strains may
have been acquired in the orphanages where the children had
stayed before adoption: the prevailing conditions, such as
overcrowding and high ESCs pressure, may have favoured such
strains. However, a study performed outside orphanages
found that one of the ESBL-producing Salmonella strains
(serotype Concord) circulating in the orphanage was also
circulating in the general population of Ethiopia [25]. In our
study, the blaSHV-2 gene was detected in the oldest strain from
1990, the blaSHV-12 gene in three strains isolated in the early
2000s, and the blaCTX-M-15 gene in all the strains isolated since
the mid 2000s. This shift from TEM/SHV to CTX-M, and in
particular to CTX-M-15, is in accordance with other epide-
miological studies of ESBL-producing Salmonella spp. in Africa
[10].
The ESBL blaCTX-M-15 gene was carried on plasmids of three
different incompatibility groups, suggesting that the dissemi-
nation of blaCTX-M-15 among Salmonella spp. in West Africa is
not due to a single type of plasmid. These plasmids were
different from the CTX-M-15/IncFII plasmid present in the
ST131 E. coli clone disseminated worldwide [26]. The most
frequent plasmid we found was a large IncHI2 ST1 similar to
pK29 [21]. It was present in ﬁve different Salmonella serotypes
from 2000 to 2008, two that produced SHV-12 and three that
produced CTX-M-15. There is currently no IncHI2 ST1
plasmid carrying the blaCTX-M-15 gene in the PubMLST data-
base, and there are only two IncHI2 pK29-like plasmids
carrying blaSHV-12 genes. These two plasmids were isolated
from E. coli and Enterobacter cloacae from humans in France
and Australia. The most probable explanation is that the
pDLST/multiplex PCR subtyping scheme for IncHI2 is too
recent (2010) to allow the database to be representative of
circulating plasmids. Large IncHI2 plasmids carrying the
blaCTX-M-15 gene have already been identiﬁed in S. enterica
serotype Concord from Ethiopia [10,27], in E. coli, Klebsiella
pneumoniae, K. oxytoca and E. cloacae in Madagascar [28] and in
Enterobacter spp. in Norway [29], and large IncHI2 plasmids
carrying the blaSHV-12 have been found in S. enterica serotype
Senftenberg from Egypt [27] and in Enterobacter spp. in
Norway [29]. All these plasmids were isolated from human
sources and were frequently associated with qnrB1 and aac
(6′)-Ib-cr genes. Frequent association of blaCTX-M-15, qnrB and
aac(6′)-Ib-cr genes has also been described in K. pneumoniae
isolates from Maghreb, West Africa, Central Africa and East
Africa, consistent with these resistance determinant genes
being carried together on the same plasmid [30].
Such accumulation of PMQR determinants (i.e. both qnrB1
and aac(6′)-Ib-cr) in ESBL-producing strains is a matter of
concern as these determinants lead to decreased susceptibility
and even full resistance to ciproﬂoxacin (MIC range 0.75–
2 mg/L) despite the absence of mutations in the QRDR.
However, the involvement of an efﬂux system such as
AcrAB-TolC and OqxAB or the presence of the qnrC gene
were not investigated and therefore cannot be excluded.
In conclusion, the data reported here add to the knowledge
of the circulation of multidrug-resistant Salmonella populations
in West Africa. Although rare, resistance to ESC and
ciproﬂoxacin is present. Therefore, it seems important to
continue monitoring antimicrobial susceptibility in Salmonella
isolates from humans, foodstuffs and food animals in Senegal.
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